Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Needles Are Out, Future Tech Is In, For Blood Glucose Measurement

Executive Summary

Medtech Insight has spoken to several companies aiming to release devices that will replace current blood glucose monitors via disruptive, innovative technologies.

You may also be interested in...



Hagar Lands Funding To Develop Noninvasive Glucose Monitoring Watch

The Israeli company touts its GWave monitor as the world's first non-invasive continuous glucose monitoring technology that uses radiofrequency waves to measure glucose levels in the blood.

Start-Up Spotlight: Grapheal Unlocking Graphene’s Potential In Wound Healing

The company has developed a biosensor that provides information to health care professionals concerning the health of a patient’s wound.

Babson Diagnostics Plans To Deliver What Theranos Could Not

Babson recently raised $31m to accelerate commercialization of its blood testing “ecosystem,” developed with help from Siemens Healthineers and Becton Dickinson.

Related Content

Topics

UsernamePublicRestriction

Register

MT143979

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel